The Role of And-1 in DNA Damage Response
The Role of And-1 in DNA Damage Response
批准号:
8691032
负责人:
Wenge Zhu
金额:
$32.89万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2019-04-30
关键词:
AffectAntineoplastic AgentsApplications GrantsBindingBiochemicalBiological AssayCell CycleCellsComplexDNADNA DamageDNA RepairDNA Synthesis InhibitionDNA biosynthesisDNA replication forkDataDevelopmentEventExhibitsGenesGenetic TranscriptionGenome StabilityHumanIn VitroKnowledgeLinkMaintenanceMammalian CellMass Spectrum AnalysisMediatingMolecularOncogenesPathway interactionsPhosphorylationPhosphotransferasesPhysiological ProcessesPlayPositioning AttributeProcessPublishingRadioRecruitment ActivityRegulationReplication OriginResistanceRoleSeriesSignal TransductionSignal Transduction PathwaySiteSolidStressStructureTechnologyTestingUltraviolet RaysWorkcancer therapycarcinogenesisdesignin vivoinnovationnovelpreventpublic health relevanceresponsesingle moleculetumorigenesisultraviolet irradiation
中文摘要
描述(由申请人提供):DNA损伤反应(DNA damage response, DDR)是一种复杂的信号转导通路,通过抵消DNA损伤的有害作用,对维持基因组稳定性和预防癌变具有极其重要的作用。在复制应激或紫外线照射下,DDR的主要事件是激活ATR和Chk1激酶,进而触发多种生理过程,包括DNA合成抑制、DNA修复、细胞周期延迟、转录等。ATR在Chk1激活和DNA合成抑制中起关键作用。然而,在哺乳动物细胞中,ATR如何与各种DDR成分协调激活Chk1,以及ATR如何靶向复制装置抑制DNA合成,在很大程度上仍然未知。我们已经证明,人类的And-1是复制叉上复制体的关键成分,用于DNA复制。我们现在有可靠的初步数据表明,and -1也参与了对DNA损伤反应的检查点和DNA合成的调节。因此,阐明And-1在DDR中的作用将填补DDR信号传导的关键知识空白。基于我们最近发表的工作和广泛的新数据,在本提案中,我们描述了一系列创新的,假设驱动的研究,以阐明人类and -1如何调节检查点激活和DNA合成以响应紫外线照射和复制应激。首先,我们将使用生化和结构分析确定and -1如何被招募到DNA损伤位点的机制。其次,我们将使用分子和结构分析确定and -1如何作为一个独特的复制体组件,通过影响多个关键DDR组件(包括ATR、Rad17、Claspin和timless - tipin)在停滞复制分叉处的相互作用来调节检查点激活。最后,我们将通过结合单分子分析、iPOND和质谱等多种尖端技术的创新方法,确定and -1调控DNA合成以应对DNA损伤的机制。鉴于靶向DNA损伤反应回路一直是抗癌药物开发的重点,所提出的工作不仅将通过识别新的成分和深入了解DNA损伤反应的机制来推进该领域,而且还将为我们开发针对and -1或and -1依赖过程的高特异性抗癌疗法提供新的策略。
英文摘要
DESCRIPTION (provided by applicant): DNA damage response (DDR) is a complex signal transduction pathway, which is extremely important to maintain genomic stability and prevent carcinogenesis by counteracting the deleterious effects of DNA damage. In response to replication stress or UV irradiation, the primary event of DDR is to activate kinases ATR and Chk1, which in turn trigger multiple physiological processes, including DNA synthesis inhibition, DNA repair, and cell cycle delay, transcription, etc. ATR plays a key role in Chk1 activation and DNA synthesis inhibition in response to DNA damage. However, how ATR coordinates with various DDR components to activate Chk1 and how ATR targets replication apparatus to inhibit DNA synthesis remain largely unknown in mammalian cells. We have demonstrated that human And-1 acts as a key component of replisome at replication forks for DNA replication. We now have solid preliminary data indicating that And-1 is also involved in the regulation of checkpoint and DNA synthesis in response to DNA damage. Thus, elucidating the role of And-1 in DDR will fill in critical knowledge gaps of DDR signaling. Building upon our recently published work and our extensive new data, in this proposal we described a series of innovative, hypothesis-driven studies to elucidate how human And-1 regulates checkpoint activation and DNA synthesis in response to UV irradiation and replication stress. First, we will determine the mechanism of how And-1 is recruited to DNA damage sites using both biochemical and structural analyses. Second, we will determine how And-1 acts as a unique replisome component to regulate checkpoint activation by impacting interplay among multiple key DDR components including ATR, Rad17, Claspin, and Timeless-Tipin at stalled replication forks using molecular and structural analyses. Finally, we will determine mechanism by which And-1 governs DNA synthesis in response to DNA damage by carrying out an innovative approach that combines multiple cutting edge technologies including single-molecule analyses, iPOND, and mass spectrometry. Given that targeting the circuitry of DNA damage response has been a key focus for the development of anti-cancer drugs, proposed work will not only advance the field by identifying new components and acquiring in-depth mechanistic understanding of DNA damage response, but also provide us with new strategies for the development of highly specific anti-cancer therapies targeting And-1 or And-1-dependent processes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of And-1 in nucleotide excision repair
-
批准号:10362967
-
项目类别:
-
资助金额:$45.58万
-
财政年份:2022
-
负责人:Wenge Zhu
-
依托单位:
The role of And-1 in nucleotide excision repair
-
批准号:10576346
-
项目类别:
-
资助金额:$44.67万
-
财政年份:2022
-
负责人:Wenge Zhu
-
依托单位:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
-
批准号:10392909
-
项目类别:
-
资助金额:$42.72万
-
财政年份:2021
-
负责人:Wenge Zhu
-
依托单位:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
-
批准号:10599218
-
项目类别:
-
资助金额:$42.72万
-
财政年份:2021
-
负责人:Wenge Zhu
-
依托单位:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
-
批准号:10117536
-
项目类别:
-
资助金额:$43.59万
-
财政年份:2021
-
负责人:Wenge Zhu
-
依托单位:
The Regulation of Cisplatin resistance in ovarian cancer
-
批准号:8916657
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2014
-
负责人:Wenge Zhu
-
依托单位:
The Regulation of Cisplatin resistance in ovarian cancer
-
批准号:8673956
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2014
-
负责人:Wenge Zhu
-
依托单位:
The Role of And-1 in DNA Damage Response
-
批准号:9271933
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2014
-
负责人:Wenge Zhu
-
依托单位:
The Regulation of Cisplatin resistance in ovarian cancer
-
批准号:9301488
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2014
-
负责人:Wenge Zhu
-
依托单位:
The Role of And-1 in DNA Damage Response
-
批准号:8848359
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2014
-
负责人:Wenge Zhu
-
依托单位:
DNA Replication Control and Its Application to Selective Killing of Cancer Cells
-
批准号:8040927
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2010
-
负责人:Wenge Zhu
-
依托单位:
DNA Replication Control and Its Application to Selective Killing of Cancer Cells
-
批准号:8220990
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2010
-
负责人:Wenge Zhu
-
依托单位:
DNA Replication Control and Its Application to Selective Killing of Cancer Cells
-
批准号:8023077
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2010
-
负责人:Wenge Zhu
-
依托单位:
海外基金